The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 327-332

  Giannelli, Gianluigi ^a,b   Iannone, Florenzo ^a   Marinosci, Felice ^a   Lapadula, Giovanni ^a   Antonaci, Salvatore ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Endothelin; Matrix metalloproteinases; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

BOSENTAN; GELATIN; GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; MEASUREMENT; MOLECULE; PATHOGENESIS; PATIENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SERUM; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; ZYMOGRAPHY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 16844373116     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X30680     Document Type: Article

References (25)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5
2. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-3
3. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29:335-9
4. Kikuchi K, Kubo M, Hoashi T, Tamaki K. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol 2002;27:301-5
5. Yazawa N, Kikuchi K, Ihn H, et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol 2000;42:70-5
6. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998;58:3743-0
7. Fridman R, Fuerst TR, Bird RE, et al. Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem 1992;267:15398-5
8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-9
9. Giannelli G, Antonaci S. Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications. Histol Histopathol 2002;17:339-5
10. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-9
11. Fata JE, Werb Z, Bissell MJ. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res 2004;6:1-11
12. Giannelli G, Quarante V, Antonaci S. Tissue remodelling in liver diseases. Histol Histopathol 2003;18:1267-74
13. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91:439-42
14. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 1993;328:1732-9
15. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62S-67S
16. Furst DE, Wilske KR, Stage DE. Results of 'satisfaction with disease control' survey. J Rheumatol 1996;23:1672-3
17. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S
18. Giannelli G, Fransvea E, Marinosci F, et al. Gelatinase levels in male and female breast cancer. Biochem Biophys Res Commun 2002;292:161-6
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 2002;346:896-903
20. Murray DB, Gardner JD, Brower GL, Janicki JS. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol 2004;287:H2295-H2299
21. Rosano L, Salani D, Di C, V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 2002;103(Suppl 48):306S-309S
22. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998;31(Suppl 1):S360-S363
23. Fakhoury H, Hillarby MC, Weiss JB. Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression. J Dermatol Sci 2002;29:62-9
24. Vieillard-Baron A, Frisdal E, et al. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 2000;87:418-25
25. Frisdal E, Gest V, Vieillard-Baron A, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001;18:838-45